Bristol-Myers Squibb: A Combined Value And Growth Story

Bristol-Myers Squibb has tumbled from about $75 last year to $56 as of Friday largely due to one failed Phase 3 study in lung cancer. This article suggests that the company's substantial Phase 1-2 pipeline could be a "freebie", given the potential value of its marketed products and other assets.